NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026. Independent, blinded biomechanical gait analyses of the CONNECT SCI study designed to differentiate genuine neural recovery from compensatory movement remain ongoing, with... The post NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates appeared first on Montreal Gazette .

Original source: Montreal Gazette